Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis

• DOI: 10.1016/j.biopha.2024.116603
• Publication Date: 2024-04-17T19:47:56Z
• Authors: Tingxuan Gu; Mengqiao Wang; Xiaorong Fu; Xueli Tian; Juanjuan Bi; Ning Lu; Chen Chen; Shijia Yan; Ang Li; Luyun Wang; Xiang Li; Kangdong Liu; Zigang Dong
• Keywords: 0301 basic medicine; 03 medical and health sciences

Novel strategies in intratumoral injection and emerging immunotherapies have heralded a new era of precise cancer treatments. The affinity SARS-CoV-2 to ACE2 receptors, feature which facilitates virulent human infection, is leveraged this research. Colon cells, with their high expression, provide potentially strategic target for using feature. While the highly expression observed several types, idea viral spike protein targeting colon cells offers novel approach treatment. Intratumoral delivery nucleic acid-based drugs promising alternative overcoming limitations existing therapies. increasing importance acids realm, use Lipid Nanoparticles (LNPs) local acid therapeutics, are important breakthroughs. LNPs protect from degradation enhance cellular uptake, making them rapidly evolving nano system precision adaptability. Our study tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) combined receptor-binding domain protein, encapsulated LNPs, cells. results indicated that TRAIL fusion-mRNA induced apoptosis vitro vivo. Collectively, our findings highlight LNP-encapsulated as potential therapy.